Aberdeen Group
PCVX icon

Aberdeen Group’s Vaxcyte PCVX Stock Holding History

Aberdeen Group’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.1M Sell
362,756
-616,213
-63% -$33.5M 0.03% 425
2026
Q1 		$56.9M Sell
978,969
-796
-0.1% -$43.2K 0.09% 188
2025
Q4 		$45.2M Buy
979,765
+256,972
+36% +$11.5M 0.07% 234
2025
Q3 		$26M Buy
722,793
+297,886
+70% +$9.87M 0.04% 355
2025
Q2 		$13.8M Buy
424,907
+160,170
+61% +$5.25M 0.02% 521
2025
Q1 		$10M Buy
264,737
+39,913
+18% +$3.19M 0.02% 563
2024
Q4 		$18.4M Buy
224,824
+141,994
+171% +$14.1M 0.03% 390
2024
Q3 		$9.46M Sell
82,830
-107,571
-56% -$9.69M 0.02% 533
2024
Q2 		$14.4M Sell
190,401
-3,831
-2% -$261K 0.03% 445
2024
Q1 		$13.3M Hold
194,232
– – 0.03% 502
2023
Q4 		$12.2M Buy
+194,232
New +$10.1M 0.03% 509

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Aberdeen Group's PCVX Position: Q2 2026 in Review

Aberdeen Group reduced its Vaxcyte (PCVX) stake by 63% in Q2 2026, selling an estimated $33.5M and leaving 362,756 shares worth $21.1M. The position accounts for 0.03% of the portfolio, ranked #425.

Aberdeen Group first reported a position in PCVX in Q4 2023 and has held it in 11 quarters since. The position peaked at $56.9M in Q1 2026. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Aberdeen Group held 362,756 shares of Vaxcyte worth $21.1M as of Q2 2026.
  • Aberdeen Group sold 616,213 Vaxcyte shares in Q2 2026, an estimated $33.5M.
  • Vaxcyte made up 0.03% of Aberdeen Group's portfolio in Q2 2026, its #425 holding.
  • Aberdeen Group first reported a position in Vaxcyte in Q4 2023 and has held it in 11 quarters since.
  • Aberdeen Group's Vaxcyte position peaked at $56.9M in Q1 2026.
  • 332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.